Table 7.
Interaction of the Pro198Leu polymorphism and cigarette smoking in NAFLD, n (%)
| Groups | Pro198Leu genotype and smoking status | |||||
|---|---|---|---|---|---|---|
| PP+PL/nonsmoking | PP+PL/SI ≤400 | PP+PL/SI >400 | LL/nonsmoking | LL/SI ≤400 | LL/SI >400 | |
| Control (n = 900) | 579 (64.33) | 53 (5.89) | 50 (5.56) | 114 (12.67) | 63 (7.00) | 41 (4.56) |
| NAFLD (n = 900) | 359 (39.89) | 39 (4.33) | 51 (5.67) | 94 (10.44) | 105 (11.67) | 252 (28.00) |
| OR* | 1.0000 | 1.1868† (ORe) | 1.6451† (ORe) | 1.3299‡ (ORg) | 2.6880§ (OReg) | 9.9129§ (OReg) |
| 95% CI | 0.7694–1.8923 | 1.2548–2.2760 | 0.9499–2.0978 | 1.9902–4.1749 | 6.5294–12.2581 | |
| β | 0.0744† (βe) | 0.2162† (βe) | 0.1238‡ (βg) | 0.4294§ (βeg) | 0.9962§ (βeg) | |
| P | 0.0861 | 0.0375 | 0.0708 | 0.0082 | 0.0043 | |
*Adjusted for sex and age; †OR (β) value by simple smoking exposure (ORe [βe]); ‡OR (β) value by simple homozygous mutant type exposure (ORg [βg]); §OR (β) value by the interaction of smoking and homozygous mutant (OReg [βeg]). NAFLD: Nonalcoholic fatty liver disease; CI: Confidence interval; OR: Odds ratio; SI: Smoking index.